David Epstein

ORCID: 0000-0002-2275-0916
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Health Systems, Economic Evaluations, Quality of Life
  • Diagnosis and Treatment of Venous Diseases
  • Cardiac, Anesthesia and Surgical Outcomes
  • Aortic aneurysm repair treatments
  • Venous Thromboembolism Diagnosis and Management
  • PI3K/AKT/mTOR signaling in cancer
  • Pharmaceutical Economics and Policy
  • Healthcare Policy and Management
  • Musicology and Musical Analysis
  • Lung Cancer Treatments and Mutations
  • Public Health and Social Inequalities
  • Healthcare cost, quality, practices
  • Global Health Care Issues
  • Global Public Health Policies and Epidemiology
  • Music Technology and Sound Studies
  • Cancer-related gene regulation
  • Cancer, Hypoxia, and Metabolism
  • Cancer Cells and Metastasis
  • Autoimmune and Inflammatory Disorders Research
  • Tendon Structure and Treatment
  • Lung Cancer Diagnosis and Treatment
  • Spondyloarthritis Studies and Treatments
  • Lipid metabolism and disorders
  • Shoulder Injury and Treatment
  • Peripheral Artery Disease Management

Universidad de Granada
2016-2025

Karolinska Institutet
2024

S:t Eriks Ögonsjukhus
2024

Duke-NUS Medical School
2014-2023

University of York
2008-2023

Morristown Medical Center
2014-2023

Ministry of Health
2023

RTI Health Solutions
2022-2023

University of Maryland, College Park
2023

United States Department of State
1984-2022

Missing data are a frequent problem in cost-effectiveness analysis (CEA) within randomised controlled trial. Inappropriate methods to handle missing can lead misleading results and ultimately affect the decision of whether an intervention is good value for money. This article provides practical guidance on how within-trial CEAs following principled approach: (i) should be based plausible assumption mechanism, i.e. probability that independent or dependent observed and/or unobserved values;...

10.1007/s40273-014-0193-3 article EN cc-by-nc PharmacoEconomics 2014-07-28

Endovascular repair of abdominal aortic aneurysm was originally developed for patients who were considered to be physically ineligible open surgical repair. Data are lacking on the question whether endovascular reduces rate death among these patients.

10.1056/nejmoa0911056 article EN New England Journal of Medicine 2010-04-12

Venous disease is the most common cause of leg ulceration. Although compression therapy improves venous ulcer healing, it does not treat underlying causes hypertension. Treatment superficial reflux has been shown to reduce rate recurrence, but effect early endovenous ablation on healing remains unclear.

10.1056/nejmoa1801214 article EN New England Journal of Medicine 2018-04-24

To assess the efficacy of endovascular aneurysm repair (EVAR) against standard alternative management in patients with large abdominal aortic (AAA).Two national, multicentre randomised trials - EVAR 1 and 2.Patients were recruited from 38 out 41 eligible UK hospitals.Men women aged at least 60 years, an AAA measuring 5.5 cm on a computerised tomography scan that was regarded as anatomically suitable for EVAR, assessed fitness open repair. Patients considered fit to or trial unfit no...

10.3310/hta16090 article EN publisher-specific-oa Health Technology Assessment 2012-02-01

There is increasing interest in potential health effects of airborne exposures to hazardous air pollutants at relatively low levels. This study focuses on sources, levels, and exposure pathways manganese, chromium, iron among inner-city high school students New York City (NYC) the contribution subways. Samples fine particulate matter (PM2.5) were collected during winter summer over 48 h periods a variety settings including inside homes, outdoors, personal samples (i.e., sampling packs...

10.1021/es034734y article EN Environmental Science & Technology 2003-12-17

Insulin-like growth factor-1 receptor (IGF-1R) is a tyrosine kinase (RTK) and critical activator of the phosphatidylinositol 3-kinase-AKT pathway. IGF-1R required for oncogenic transformation tumorigenesis. These observations have spurred anticancer drug discovery development efforts both biological small-molecule inhibitors. The ability one RTK to compensate another maintain tumor cell viability emerging as common resistance mechanism antitumor agents targeting individual RTKs. As...

10.1158/1535-7163.mct-10-0318 article EN Molecular Cancer Therapeutics 2010-10-01

Epithelial-mesenchymal transition (EMT) is an important contributor to the invasion and metastasis of epithelial-derived cancers. While considerable effort has focused in regulators involved process, we have on consequences EMT prosurvival signaling. Changes distinct metastable 'epigentically-fixed' states were measured by correlation protein, phosphoprotein, phosphopeptide RNA transcript abundance. The assembly 1167 modulated components into functional systems or machines simplified...

10.1007/s10585-010-9367-3 article EN cc-by-nc Clinical & Experimental Metastasis 2010-12-30

Epidermal growth factor receptor (EGFR) and insulin-like factor-I (IGF-IR) can cooperate to regulate tumor survival, synergistic inhibition has been reported for combined blockade of EGFR IGF-IR. However, in preclinical models, only a subset tumors exhibit high sensitivity this combination, highlighting the potential need patient selection optimize clinical efficacy. Herein, we have characterized molecular basis cooperative upon dual IGF-IR provide biomarkers that seem differentiate...

10.1158/0008-5472.can-07-6720 article EN Cancer Research 2008-10-15

NSCLC cells with a mesenchymal phenotype have shown marked reduction in sensitivity to EGFR inhibitors, though the molecular rationale has remained obscure. Here we find that mesenchymal-like tumor both tyrosine phosphorylation of EGFR, ErbB2, and ErbB3 signaling networks expression family ligands were decreased. While chronic activation can promote an EMT-like transition, once having occurred was attenuated. We investigated mechanisms by which bypass acquire alternative routes proliferative...

10.1007/s10585-008-9200-4 article EN cc-by-nc Clinical & Experimental Metastasis 2008-08-11

Abstract The phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway is frequently activated in human cancers, and mTOR a clinically validated target. forms two distinct multiprotein complexes, mTORC1 mTORC2, which regulate cell growth, metabolism, proliferation, survival. Rapamycin its analogues partially inhibit through allosteric binding to mTORC1, but not have shown clinical utility certain cancers. Here, we report the preclinical characterization of OSI-027, selective potent dual inhibitor...

10.1158/1535-7163.mct-10-1099 article EN Molecular Cancer Therapeutics 2011-06-15

Abstract Inhibition of platelet derived growth factor (PDGF) can increase the efficacy other cancer therapeutics, but cellular mechanism is incompletely understood. We examined effects on tumor vasculature a novel DNA oligonucleotide aptamer (AX102) that selectively binds PDGF-B. Treatment with AX102 led to progressive reduction pericytes, identified by PDGF receptor β, NG2, desmin, or α-smooth muscle actin immunoreactivity, in Lewis lung carcinomas. The decrease ranged from 35% at 2 days,...

10.1158/0008-5472.can-07-0293 article EN Cancer Research 2007-08-01

Background Short-term survival benefits of endovascular aneurysm repair (EVAR) compared with open (OR) intact abdominal aortic aneurysms have been shown in randomised trials, but this early benefit is soon lost. Survival EVAR was unclear at follow-up to 10 years. Objective To assess the long-term efficacy against OR patients deemed fit and suitable for both procedures (EVAR trial 1; EVAR-1); no intervention unfit 2; EVAR-2). appraise significance type II endoleak define criteria...

10.3310/hta22050 article EN publisher-specific-oa Health Technology Assessment 2018-01-01

ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTDynamics of the Dihydrofolate Reductase-Folate Complex: Catalytic Sites and Regions Known To Undergo Conformational Change Exhibit Diverse Dynamical FeaturesDavid M. Epstein, Stephen J. Benkovic, Peter E. WrightCite this: Biochemistry 1995, 34, 35, 11037–11048Publication Date (Print):September 5, 1995Publication History Published online1 May 2002Published inissue 5 September...

10.1021/bi00035a009 article EN Biochemistry 1995-09-05

To evaluate the clinical effectiveness, cost-effectiveness and safety of a policy relatively early laparoscopic surgery compared with continued medical management amongst people gastro-oesophageal reflux disease (GORD) judged suitable for both policies.Relative effectiveness was assessed by randomised trial (with parallel non-randomised preference groups) comparing surgery-based policy. The economic evaluation two policies in order to identify most efficient provision future care describe...

10.3310/hta12310 article EN publisher-specific-oa Health Technology Assessment 2008-09-01

Abstract The mammalian target of rapamycin (mTOR) pathway is implicated widely in cancer pathophysiology. Dual inhibition the mTOR kinase complexes mTORC1 and mTORC2 decreases tumor xenograft growth vivo VEGF secretion vitro, but relationship between these two effects are unclear. In this study, we examined mTORC1/2 dual on production, angiogenesis, vascular regression, regrowth, compared to alone. ATP-competitive inhibitors OSI-027 OXA-01 targeted both signaling vitro vivo, unlike that only...

10.1158/0008-5472.can-10-3126 article EN Cancer Research 2011-03-01
Coming Soon ...